Patents by Inventor Isabelle Camby

Isabelle Camby has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of a galectin-1-targeted RNAi-based approach for the treatment of cancer
    Patent number: 7964575
    Abstract: The present invention relates to an RNAi molecule suitable for reducing the expression of galectin-1 containing any of the sequences of SEQ ID NOs: 1-33, and preferably the sequences of SEQ ID NO: 2, 3, or 4, and to the use thereof as a medicament, or for the manufacture of a medicament for treating and/or for delaying the progression of cancer, preferably glioma, pancreatic cancer, head and neck cancer, melanoma, non-small-cell lung cancer and non-Hodgkin's lymphoma.
    Type: Grant
    Filed: March 9, 2006
    Date of Patent: June 21, 2011
    Assignees: Universite Libre de Bruxelles, Universite Catholique de Louvain
    Inventors: Isabelle Camby, Patrick Henriet, Florence Lefranc, Pierre Courtoy, Robert Kiss
  • USE OF A GALECTIN-1-TARGETED RNAI-BASED APPROACH FOR THE TREATMENT OF CANCER
    Publication number: 20100120891
    Abstract: The present invention relates to an RNAi molecule suitable for reducing the expression of galectin-1 containing any of the sequences of SEQ ID NOs: 1-33, and preferably the sequences of SEQ ID NO: 2, 3, or 4, and to the use thereof as a medicament, or for the manufacture of a medicament for treating and/or for delaying the progression of cancer, preferably glioma, pancreatic cancer, head and neck cancer, melanoma, non-small-cell lung cancer and non-Hodgkin's lymphoma.
    Type: Application
    Filed: March 9, 2006
    Publication date: May 13, 2010
    Applicants: UNIVERSITE LIBRE DE BRUXELLES, UNIVERSITE CATHOLIQUE DE LOUVAIN
    Inventors: Isabelle Camby, Patrick Henriet, Florence Lefranc, Pierre Courtoy, Robert Kiss